The Effectiveness of a Modified Complete Decongestive Therapy Program in the Treatment of Lymphedema Cases

2011 ◽  
Vol 18 (4) ◽  
pp. 37-51
Author(s):  
Sabah Moshref ◽  
Safaa Mahran
2018 ◽  
Vol 99 (4) ◽  
pp. 406-410
Author(s):  
Sehim Kutlay ◽  
Elif Can Ozdemir ◽  
Zahide Pala ◽  
Selin Ozen ◽  
Hatice Sanli

2015 ◽  
Vol 01 (02) ◽  
pp. 077-083 ◽  
Author(s):  
Ashish Goel ◽  
Juhi Agarwal ◽  
Sandeep Mehta ◽  
Kapil Kumar

ABSTRACTBreast cancer related lymphedema (BCRL) is a chronic debilitating condition seen after treatment of breast cancer. The overall incidence varies from 20% to 56% in all patients treated for breast cancer. Every patient is at a lifelong risk for BCRL and the risk goes on increasing as the followup period increases. Locoregional treatment including surgery or radiotherapy is the most common risk factor for development of arm lymphedema. There are two phases of arm lymphedema. There is increased fluid accumulation in the fluid phase of lymphedema which later on goes into the solid phase where fat and fibrotic tissue is deposited in the subcutaneous tissue. The treatment of BCRL is a challenge both for the patient and the treating surgeon and it needs multidisciplinary team work to be successful. Non-surgical treatment modalities include complete decongestive therapy (CDT) and pneumatic compression therapy. Surgery for BCRL is usually undertaken as a salvage modality after failure of conservative approaches. The surgical spectrum for BCRL varies from extensive excisional operations which were commonly done in the past to newer methods like suction assisted protein lipectomy, lymphatic reconstruction and vascular lymph node transfer (VLNT) using super-microsurgical techniques. There is no consensus regarding the preference of one procedure over other due to lack of randomised control trials. It is however suggested to do lymphovenous anastomosis and complete decongestive therapy for early cases in fluid phase; while patients in the solid phase may be treated with a combination of liposuction with CDT or VLNT alone.


Lymphedema ◽  
2011 ◽  
pp. 229-236 ◽  
Author(s):  
Etelka Földi ◽  
Martha Földi

Phlebologie ◽  
2015 ◽  
Vol 44 (03) ◽  
pp. 134-138 ◽  
Author(s):  
O. Gültig

ZusammenfassungIm Unterschied zum wissenschaftlich anerkannten Stellenwert der KPE (Phase I + II) in der Behandlung primärer und sekundärer Lymphödeme als Therapie der Wahl, ist die initiale Entstauung des Phlebolymphödems (Stadium II + III a/b der CVI nach Widmer / CEAP IV-VI) unter ambulanten Bedingungen häuft unbekannt. Als Prävention für das weitere Voranschreiten der veno-lymphostatischen Erkrankung und der Entwicklung des Ulcus cruris venosum wurde die Entstauungsphase (Phase I der KPE) bereits vor einem Jahrzehnt durch den Bundesausschuss Ärzte-Krankenkassen in die geltenden Heilmittelrichtlinien unter LY 1 und LY 2 aufgenommen. Erst nach einer durchschnittlichen 10- bis max. 15-malig durchgeführten tägli-chen KPE-Phase I ist die Versorgung mit dem unverzichtbaren med. Kompressionsstrumpf sinnvoll. Die konstante Weiterbehandlung als KPE-Phase II (Erhaltungsphase) ist nur in einigen Ausnahmefällen, nach entsprechendem ärztlichem Befund, notwendig.


Sign in / Sign up

Export Citation Format

Share Document